OPKO Health, Inc.OPK stock score: 33/100
$1.61 · -4.73% · Scored Nov 19, 2026
- Technical
- 49
- Fundamental
- 29
- News
- 57
The reading
OPKO Health (OPK) scores 33 out of 100, which reads bearish, higher than 7% of Healthcare stocks and 8% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 29, technicals 49.
Among the fundamentals, Price Target at 100 and Current Ratio at 99 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 46 and contrarian oscillators 57.
News sentiment is neutral at 57; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 31 to 44, and it is down 10 points over the period.
About OPKO Health
OPKO Health (OPK) is a healthcare company with pharmaceutical and diagnostics businesses. Its pharmaceutical products include Rayaldee, an extended-release vitamin D prohormone for secondary hyperparathyroidism in adults with chronic kidney disease, and NGENLA, a once-weekly growth hormone developed by OPKO and commercialized by Pfizer, with OPKO sharing in its economics. The company also sells pharmaceutical products through operations outside the United States and earns royalties under agreements with partners. Through its ModeX Therapeutics subsidiary, OPKO develops multispecific antibodies and vaccines for cancer and infectious diseases, in some cases with larger drug company partners such as Regeneron. Its diagnostics business, BioReference Health, provides laboratory testing and offers the 4Kscore test for prostate cancer risk. OPKO has been selling its BioReference diagnostic operations to Labcorp in stages.
OPKO competes with growth hormone makers such as Novo Nordisk and Ascendis Pharma, with other treatments for kidney disease complications and, in diagnostics, with large laboratories such as Quest Diagnostics. Its edge rests on a portfolio that combines marketed products, partner royalties and an early-stage drug development platform. Investors who follow OPK stock tend to watch Rayaldee sales and NGENLA results reported through its partnership with Pfizer. Progress at ModeX and its partnership milestones is closely followed. The exit from diagnostics, cash use, debt and share buybacks are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward OPK’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
29Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
51Pulling it up
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
- SMA 20090
Simple Moving Average (200-period) is the most widely followed long-term trend indicator.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
- VWAP0
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 57
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 36 | 1 |
| Daily | 51 | 3 |
| Weekly | 63 | 2 |
| Monthly | 46 | 2 |
| Quarterly | 41 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 20, 2026 | 33 |
| Nov 19, 2026 | 33 |
| Nov 18, 2026 | 32 |
| Nov 15, 2026 | 33 |
| Nov 14, 2026 | 33 |
| Nov 13, 2026 | 32 |
| Nov 12, 2026 | 41 |
| Nov 11, 2026 | 40 |
| Nov 7, 2026 | 44 |
| Nov 6, 2026 | 43 |
| Nov 5, 2026 | 43 |
| Nov 4, 2026 | 44 |
| Nov 3, 2026 | 44 |
| Nov 1, 2026 | 43 |
| Oct 30, 2026 | 42 |
| Oct 29, 2026 | 42 |
| Oct 28, 2026 | 42 |
| Oct 27, 2026 | 42 |
| Oct 25, 2026 | 42 |
| Oct 24, 2026 | 42 |
| Oct 23, 2026 | 42 |
| Oct 22, 2026 | 41 |
| Oct 21, 2026 | 42 |
| Oct 19, 2026 | 42 |
| Oct 18, 2026 | 42 |
| Oct 17, 2026 | 42 |
| Oct 16, 2026 | 44 |
| Oct 15, 2026 | 33 |
| Oct 14, 2026 | 31 |
| Oct 13, 2026 | 34 |
| Oct 11, 2026 | 33 |
| Oct 10, 2026 | 33 |
| Oct 9, 2026 | 33 |
| Oct 8, 2026 | 33 |
| Oct 7, 2026 | 38 |
| Oct 6, 2026 | 40 |
| Oct 4, 2026 | 40 |
| Oct 3, 2026 | 40 |
| Oct 2, 2026 | 40 |
| Oct 1, 2026 | 40 |
| Sep 30, 2026 | 41 |
| Sep 29, 2026 | 41 |
| Sep 28, 2026 | 41 |
| Sep 27, 2026 | 42 |
| Sep 26, 2026 | 42 |
| Sep 25, 2026 | 42 |
| Sep 24, 2026 | 43 |
| Sep 23, 2026 | 44 |
| Sep 21, 2026 | 44 |
| Sep 20, 2026 | 44 |
| Sep 19, 2026 | 44 |
| Sep 18, 2026 | 44 |
| Sep 17, 2026 | 42 |
| Sep 15, 2026 | 42 |
| Sep 13, 2026 | 43 |
| Sep 12, 2026 | 43 |
| Sep 11, 2026 | 43 |
| Sep 10, 2026 | 40 |
| Sep 9, 2026 | 42 |
| Sep 8, 2026 | 43 |
| Sep 6, 2026 | 44 |
| Sep 5, 2026 | 44 |
| Sep 4, 2026 | 44 |
| Sep 2, 2026 | 44 |
| Sep 1, 2026 | 43 |
| Aug 31, 2026 | 40 |
| Aug 29, 2026 | 41 |
| Aug 28, 2026 | 42 |
| Aug 27, 2026 | 42 |
| Aug 26, 2026 | 41 |
| Aug 25, 2026 | 41 |
| Aug 23, 2026 | 43 |
Key facts
- Market cap
- $1.2B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Beta
- 1.53
- Risk grade (1–10)
- 7
- Next earnings
- Nov 4, 2026
Diagnostics & Research peers
| Company | Market cap | Score |
|---|---|---|
| CDNA CareDx | $3.8B | 59 |
| VCYT Veracyte | $2.0B | 64 |
| NEO NeoGenomics | $2.0B | 51 |
| PSNL Personalis | $1.6B | 45 |
| WGS GeneDx Holdings | $1.5B | 50 |
| CSTL Castle Biosciences | $1.0B | 58 |
Questions
What is OPK's stock rating today?
OPK scores 33/100 (Bearish) as of Nov 19, 2026: technical 49, fundamental 29, and news sentiment 57, which is shown but not counted. Scores are recomputed every night.
What does OPKO Health do?
OPKO Health (OPK) is a healthcare company with pharmaceutical and diagnostics businesses. Its pharmaceutical products include Rayaldee, an extended-release vitamin D prohormone for secondary hyperparathyroidism in adults with chronic kidney disease, and NGENLA, a once-weekly growth hormone developed by OPKO and commercialized by Pfizer, with OPKO sharing in its economics.
Is OPK stock a buy?
The score is not a buy or sell recommendation. A 33 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the OPK score calculated?
100 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/opk/"><img src="https://stocksscores.com/stocks/opk/badge.svg" alt="OPK stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/opk/)